Gyros AB and Kratos Analytical begin development collaboration.
Gyros AB today announced a collaboration agreement with Kratos Analytical to develop a microlaboratory for sample preparation prior to analysis by mass spectrometry to be based on the Gyros microfluidic technology platform. The microlaboratory will be compatible with the Axima-QITTM and Axima-CFRTM line of mass spectrometry workstations from Kratos.
Gyros have developed a miniaturized and fully integrated process for sample preparation prior to MALDI mass spectrometry, using a microlaboratory, Gyrolab MALDI SP1, in the form of a compact disk (CD). Protein digests are concentrated, purified and crystallized directly onto target areas on the CD under the control of Gyrolab Workstation. The CD is then transferred to a MALDI mass spectrometer for sample analysis and identification.
“This collaboration is an example of the strong interest stimulated by Gyrolab MALDI and our technology platform within the mass spectrometry community.” explained Maris Hartmanis, President and CEO at Gyros AB, “We have shown that preparation using Gyros technology produces samples that can be analyzed at sensitivity levels close to the detection limit of today’s MALDI mass spectrometers. Entering into a research and development collaboration with one of the leading global suppliers of mass spectrometers will enable more users to increase their success rate for protein identification, particularly when working with low abundant proteins.”
“A key part of the Kratos strategy is to increase the versatility of the Axima range of MALDI mass spectrometers by increasing the range of applications.” says Katsu Ichimura, Managing Director of Kratos Analytical. “Making MALDI compatible with a wide variety of sample preparation formats is critical to this. Gyros technology represents a new and exciting approach to biomolecular separation, in which MALDI is the mass spectrometry technique of choice for subsequent detection of the separated analytes. The near-perpendicular laser alignment (relative to the target) of the Axima products, automated data acquisition (IntelliMarqueTM) and low extraction field of the Axima-QITTM (compatible with non-conducting materials) will offer additional benefits for users of Gyrolab MALDI SP1 microlaboratory.”
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: email@example.com / firstname.lastname@example.org
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.